307 related articles for article (PubMed ID: 28212996)
1. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
2. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China.
Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN
Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452
[TBL] [Abstract][Full Text] [Related]
4. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
5. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
6. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center.
Okuma Y; Hosomi Y; Watanabe K; Yamada Y; Horio H; Maeda Y; Okamura T; Hishima T
BMC Cancer; 2014 May; 14():349. PubMed ID: 24885581
[TBL] [Abstract][Full Text] [Related]
8. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathologic analysis of 52 cases of thymic epithelial tumor].
Ma YQ; Miao N; Abulajiang G; Li QX; Liu X; Zhang W; Wang CF; Wang J
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):249-54. PubMed ID: 20654124
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor expression in thymic malignancies.
Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
[TBL] [Abstract][Full Text] [Related]
11. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in thymic epithelial malignancies.
Palmieri G; Marino M; Buonerba C; Federico P; Conti S; Milella M; Petillo L; Evoli A; Lalle M; Ceribelli A; Merola G; Matano E; Sioletic S; De Placido S; Di Lorenzo G; Damiano V
Cancer Chemother Pharmacol; 2012 Feb; 69(2):309-15. PubMed ID: 21710245
[TBL] [Abstract][Full Text] [Related]
13. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
[TBL] [Abstract][Full Text] [Related]
14. A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features.
Kim BK; Cho BC; Choi HJ; Sohn JH; Park MS; Chang J; Kim SK; Kim DJ; Chung KY; Lee CG; Kim JH; Yoo NC
Oncol Rep; 2008 Jun; 19(6):1525-31. PubMed ID: 18497960
[TBL] [Abstract][Full Text] [Related]
15. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.
Fukumoto K; Taniguchi T; Ishikawa Y; Kawaguchi K; Fukui T; Kato K; Matsuo K; Yokoi K
Eur J Cardiothorac Surg; 2012 Dec; 42(6):e152-6. PubMed ID: 23024234
[TBL] [Abstract][Full Text] [Related]
16. [Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France].
Hadoux J; Girard N; Besse B
Bull Cancer; 2012 Nov; 99(11):1045-55. PubMed ID: 23131309
[TBL] [Abstract][Full Text] [Related]
17. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase receptor expression in thymomas.
Henley JD; Cummings OW; Loehrer PJ
J Cancer Res Clin Oncol; 2004 Apr; 130(4):222-4. PubMed ID: 14762710
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors].
Wang Y; Ueda Y; Shimasaki M; Liu N; Wang EH
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):18-23. PubMed ID: 16608644
[TBL] [Abstract][Full Text] [Related]
20. Histogenetic and disease-relevant phenotypes in thymic epithelial tumors (TETs): The potential significance for future TET classification.
Yamada Y
Pathol Int; 2023 Jul; 73(7):265-280. PubMed ID: 37278579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
